Our Pricing

Wegovy vs Mounjaro: Clinical Evidence & UK Results

Published on: June 03, 2026

When comparing wegovy vs mounjaro uk results, the clinical evidence shows distinct differences in weight loss outcomes, mechanisms of action, and patient experiences. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these options with transparent pricing and expert guidance. Both medications are MHRA-licensed prescription treatments that require clinical assessment by a UK prescriber before dispensing.

How Mounjaro and Wegovy Work Differently

Mounjaro (tirzepatide) represents a significant advancement as the UK's first dual GIP/GLP-1 receptor agonist, activating two distinct hormonal pathways that regulate appetite, blood glucose, and energy metabolism [1]. This dual mechanism distinguishes it from single-pathway treatments and contributes to its enhanced clinical profile.

Wegovy (semaglutide) works through GLP-1 receptor activation alone, mimicking the natural glucagon-like peptide-1 hormone that reduces appetite and slows gastric emptying [2]. Both medications are administered as once-weekly subcutaneous injections, but their different mechanisms produce varying clinical outcomes in UK patients.

The dual-action approach of tirzepatide appears to produce more pronounced effects on insulin sensitivity and hepatic glucose production compared to GLP-1-only agonists, which may explain the superior weight loss results observed in head-to-head comparisons [1][3].

Clinical Trial Results: Wegovy vs Mounjaro UK Evidence

The SURMOUNT-1 trial demonstrated that Mounjaro patients achieved average weight reductions of 15.0%, 19.5%, and 20.9% at the 5mg, 10mg, and 15mg doses respectively over 72 weeks [1]. These results represent some of the highest efficacy figures recorded for any weight loss medication currently licensed in the UK.

In comparison, the STEP-1 trial for Wegovy showed an average 14.9% body weight reduction at the 2.4mg maintenance dose over 68 weeks [2]. While this represents clinically significant weight loss, the difference between the two medications becomes more apparent at higher dose comparisons.

Head-to-head data from the SURPASS-2 trial, which compared tirzepatide directly against semaglutide 1.0mg (the diabetes formulation), showed tirzepatide patients lost significantly more weight across all dose levels [3]. UK patients should note that individual results vary based on adherence, lifestyle modifications, and metabolic factors.

Real-World UK Patient Outcomes

Beyond controlled trials, UK prescribing data suggests both medications produce meaningful weight loss when combined with dietary changes and increased physical activity. Our clinical team at Cured Pharmacy observes that patients who maintain consistent injection schedules and engage with lifestyle support typically achieve results within the ranges reported in clinical trials, subject to individual variation.

Side Effects and Tolerability Comparison

Both medications share similar gastrointestinal side effect profiles, with nausea being the most commonly reported adverse event in clinical trials [1][2]. However, the incidence and severity can differ between the two treatments and typically diminish as patients adjust to therapy.

In the SURMOUNT-1 trial, nausea occurred in 29% of Mounjaro patients at the 10mg dose, while STEP-1 reported nausea in 44% of Wegovy patients at 2.4mg [1][2]. Gastrointestinal side effects including diarrhoea, constipation, and vomiting were reported with both medications, though individual tolerance varies considerably.

UK prescribers typically initiate treatment at low doses with gradual escalation to minimise side effects. At Cured Pharmacy, our clinical team provides comprehensive guidance on managing common adverse events, including dietary modifications and timing strategies that may improve tolerability throughout the titration period.

Managing Side Effects Effectively

Most gastrointestinal symptoms resolve within 4-8 weeks as the body adjusts to treatment. Patients who experience persistent or severe side effects should contact their prescriber, as dose adjustments or alternative treatments may be appropriate. Neither medication should be used during pregnancy or in patients with a personal or family history of medullary thyroid carcinoma.

Dosing Schedules and Treatment Protocols

Mounjaro follows a structured escalation schedule starting at 2.5mg weekly for four weeks, then increasing to 5mg, with potential further increases to 10mg or 15mg based on clinical response and tolerability [4]. This gradual approach allows the body to adapt whilst minimising gastrointestinal side effects.

Wegovy initiates at 0.25mg weekly, escalating through 0.5mg, 1.0mg, and 1.7mg doses before reaching the 2.4mg maintenance dose, typically over 16-20 weeks [2]. The slower titration schedule reflects the medication's potency and helps optimise patient tolerance throughout the dose-escalation phase.

Both medications require consistent weekly administration on the same day each week for optimal results. UK patients should inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites to reduce the risk of lipodystrophy. Missed doses should be administered within 5 days for Wegovy and 4 days for Mounjaro; otherwise, patients should skip the missed dose and resume their regular schedule.

Cost Considerations and UK Availability

At Cured Pharmacy, Mounjaro is available from £124.99 per pen with transparent upfront pricing before your free consultation. We guarantee the lowest prices in the UK for genuine, MHRA-licensed medications dispensed by our UK-registered clinical team under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Treatment costs vary based on your prescribed dose and treatment duration. Both Mounjaro and Wegovy require ongoing use to maintain weight loss results, and UK patients should factor long-term costs into their treatment decision. Our clinical team ensures you receive the most appropriate medication based on your medical history, weight loss goals, and individual circumstances rather than cost alone.

Supply availability for both medications has improved significantly across UK pharmacies following manufacturing expansions. Cured Pharmacy maintains consistent stock levels and provides discreet next-day delivery throughout the UK, ensuring treatment continuity for our patients.

Prescription Requirements and Assessment Process

All weight loss injections are prescription-only medicines in the UK and require clinical assessment by a registered prescriber. Our online consultation takes under 3 minutes and is reviewed by UK-registered clinicians who assess your suitability based on BMI, medical history, current medications, and contraindications. Prescriptions are only issued when clinically appropriate and safe.

Which Treatment Is Right for You?

The choice between Wegovy and Mounjaro depends on multiple clinical factors including your weight loss goals, previous treatment responses, side effect tolerance, and medical history. Clinical trial data suggests Mounjaro may produce greater absolute weight loss, particularly at higher doses, whilst Wegovy offers proven efficacy with an established UK prescribing history [1][2][3].

UK prescribers consider your BMI, comorbidities such as type 2 diabetes or cardiovascular disease, and any contraindications when recommending treatment. Patients with type 2 diabetes may particularly benefit from Mounjaro's dual mechanism, which demonstrates superior glycaemic control compared to GLP-1-only agonists [3].

At Cured Pharmacy, our clinical team provides personalised recommendations based on your individual circumstances. Both medications require commitment to lifestyle modifications including reduced calorie intake and increased physical activity to achieve optimal results. Your prescriber will monitor your progress and adjust treatment as needed to ensure safe, effective weight management.

Starting Your Weight Loss Journey

Begin with our free online consultation, which takes under 3 minutes to complete. Our UK-registered prescribers will review your medical information and recommend the most appropriate treatment option. If approved, your medication is dispensed from our UK pharmacy with discreet packaging and next-day delivery. Ongoing clinical support is available throughout your treatment journey.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss medications work best when combined with reduced calorie intake and increased physical activity.